BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Keating GM. Bevacizumab: a review of its use in advanced cancer. Drugs 2014;74:1891-925. [PMID: 25315029 DOI: 10.1007/s40265-014-0302-9] [Cited by in Crossref: 106] [Cited by in F6Publishing: 92] [Article Influence: 15.1] [Reference Citation Analysis]
Number Citing Articles
1 Mossenta M, Busato D, Baboci L, Cintio FD, Toffoli G, Bo MD. New Insight into Therapies Targeting Angiogenesis in Hepatocellular Carcinoma. Cancers (Basel) 2019;11:E1086. [PMID: 31370258 DOI: 10.3390/cancers11081086] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 6.7] [Reference Citation Analysis]
2 Mazzola CR, Chin J. Targeting the VEGF pathway in metastatic bladder cancer. Expert Opinion on Investigational Drugs 2015;24:913-27. [DOI: 10.1517/13543784.2015.1041588] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 4.0] [Reference Citation Analysis]
3 Greening DW, Lee ST, Ji H, Simpson RJ, Rigopoulos A, Murone C, Fang C, Gong S, O'Keefe G, Scott AM. Molecular profiling of cetuximab and bevacizumab treatment of colorectal tumours reveals perturbations in metabolic and hypoxic response pathways. Oncotarget 2015;6:38166-80. [PMID: 26517691 DOI: 10.18632/oncotarget.6241] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
4 Kalainayakan SP, Ghosh P, Dey S, Fitzgerald KE, Sohoni S, Konduri PC, Garrossian M, Liu L, Zhang L. Cyclopamine tartrate, a modulator of hedgehog signaling and mitochondrial respiration, effectively arrests lung tumor growth and progression. Sci Rep 2019;9:1405. [PMID: 30723259 DOI: 10.1038/s41598-018-38345-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
5 Afrin H, Salazar CJ, Kazi M, Ahamad SR, Alharbi M, Nurunnabi M. Methods of screening, monitoring and management of cardiac toxicity induced by chemotherapeutics. Chinese Chemical Letters 2022. [DOI: 10.1016/j.cclet.2022.01.011] [Reference Citation Analysis]
6 Watson N, Al-Samkari H. Thrombotic and bleeding risk of angiogenesis inhibitors in patients with and without malignancy. J Thromb Haemost 2021;19:1852-63. [PMID: 33928747 DOI: 10.1111/jth.15354] [Reference Citation Analysis]
7 Basu A, Kodumudi K. Multimodal approaches to improve immunotherapy in breast cancer. Immunotherapy 2020;12:161-5. [PMID: 32157934 DOI: 10.2217/imt-2019-0198] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Rimkus TK, Carpenter RL, Qasem S, Chan M, Lo HW. Targeting the Sonic Hedgehog Signaling Pathway: Review of Smoothened and GLI Inhibitors. Cancers (Basel) 2016;8:E22. [PMID: 26891329 DOI: 10.3390/cancers8020022] [Cited by in Crossref: 314] [Cited by in F6Publishing: 296] [Article Influence: 52.3] [Reference Citation Analysis]
9 Zhang CH, Li M, Lin YP, Gao Q. Systemic Therapy for Hepatocellular Carcinoma: Advances and Hopes. Curr Gene Ther 2020;20:84-99. [PMID: 32600231 DOI: 10.2174/1566523220666200628014530] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Safarzadeh Kozani P, Safarzadeh Kozani P, Rahbarizadeh F. Addressing the obstacles of CAR T cell migration in solid tumors: wishing a heavy traffic. Crit Rev Biotechnol 2021;:1-20. [PMID: 34957875 DOI: 10.1080/07388551.2021.1988509] [Reference Citation Analysis]
11 Falzone L, Salomone S, Libra M. Evolution of Cancer Pharmacological Treatments at the Turn of the Third Millennium. Front Pharmacol. 2018;9:1300. [PMID: 30483135 DOI: 10.3389/fphar.2018.01300] [Cited by in Crossref: 192] [Cited by in F6Publishing: 174] [Article Influence: 48.0] [Reference Citation Analysis]
12 Mealy MA, Shin K, John G, Levy M. Bevacizumab is safe in acute relapses of neuromyelitis optica. Clin Exp Neuroimmunol 2015;6:413-8. [PMID: 26834844 DOI: 10.1111/cen3.12239] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 2.9] [Reference Citation Analysis]
13 Lin AL, Donoghue MTA, Wardlaw SL, Yang TJ, Bodei L, Tabar V, Geer EB. Approach to the Treatment of a Patient with an Aggressive Pituitary Tumor. J Clin Endocrinol Metab 2020;105:dgaa649. [PMID: 32930787 DOI: 10.1210/clinem/dgaa649] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
14 Barredo GR, Giudicessi SL, Martínez Ceron MC, Saavedra SL, Rodriguez S, Filgueira Risso L, Erra-Balsells R, Mahler G, Albericio F, Cascone O, Camperi SA. A short peptide fragment of the vascular endothelial growth factor as a novel ligand for bevacizumab purification. Protein Expr Purif 2020;165:105500. [PMID: 31542564 DOI: 10.1016/j.pep.2019.105500] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Gao J, Hu H, Wang X. Clinically relevant concentrations of lidocaine inhibit tumor angiogenesis through suppressing VEGF/VEGFR2 signaling. Cancer Chemother Pharmacol 2019;83:1007-15. [PMID: 30887179 DOI: 10.1007/s00280-019-03815-4] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
16 Turco S, El Kaffas A, Zhou J, Lutz AM, Wijkstra H, Willmann JK, Mischi M. Pharmacokinetic Modeling of Targeted Ultrasound Contrast Agents for Quantitative Assessment of Anti-Angiogenic Therapy: a Longitudinal Case-Control Study in Colon Cancer. Mol Imaging Biol 2019;21:633-43. [PMID: 30225758 DOI: 10.1007/s11307-018-1274-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
17 Cooper E, Choi PJ, Denny WA, Jose J, Dragunow M, Park TI. The Use of Heptamethine Cyanine Dyes as Drug-Conjugate Systems in the Treatment of Primary and Metastatic Brain Tumors. Front Oncol 2021;11:654921. [PMID: 34141613 DOI: 10.3389/fonc.2021.654921] [Reference Citation Analysis]
18 Abdelbaky SB, Ibrahim MT, Samy H, Mohamed M, Mohamed H, Mustafa M, Abdelaziz MM, Forrest ML, Khalil IA. Cancer immunotherapy from biology to nanomedicine. J Control Release 2021;336:410-32. [PMID: 34171445 DOI: 10.1016/j.jconrel.2021.06.025] [Reference Citation Analysis]
19 Bailey CE, Parikh AA. Assessment of the risk of antiangiogenic agents before and after surgery. Cancer Treatment Reviews 2018;68:38-46. [DOI: 10.1016/j.ctrv.2018.05.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
20 Soheilifar MH, Taheri RA, Zolfaghari Emameh R, Moshtaghian A, Kooshki H, Motie MR. Molecular Landscape in Alveolar Soft Part Sarcoma: Implications for Molecular Targeted Therapy. Biomedicine & Pharmacotherapy 2018;103:889-96. [DOI: 10.1016/j.biopha.2018.04.117] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
21 Drooger JC, van Tinteren H, de Groot SM, Ten Tije AJ, de Graaf H, Portielje JE, Jager A, Honkoop A, Linn SC, Kroep JR, Erdkamp FL, Hamberg P, Imholz AL, van Rossum-Schornagel QC, Heijns JB, van Leeuwen-Stok AE, Sleijfer S. A randomized phase 2 study exploring the role of bevacizumab and a chemotherapy-free approach in HER2-positive metastatic breast cancer: The HAT study (BOOG 2008-2003), a Dutch Breast Cancer Research Group trial. Cancer 2016;122:2961-70. [PMID: 27315546 DOI: 10.1002/cncr.30141] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
22 Xie Q, Sun M, Sun J, Zheng T, Wang M. New progress in the treatment of neuromyelitis optica spectrum disorder with monoclonal antibodies (Review). Exp Ther Med 2021;21:148. [PMID: 33456515 DOI: 10.3892/etm.2020.9579] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
23 Motz KM, Hillel AT. Office-based Management of Recurrent Respiratory Papilloma. Curr Otorhinolaryngol Rep 2016;4:90-8. [PMID: 27242951 DOI: 10.1007/s40136-016-0118-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
24 Kintzing JR, Filsinger Interrante MV, Cochran JR. Emerging Strategies for Developing Next-Generation Protein Therapeutics for Cancer Treatment. Trends Pharmacol Sci 2016;37:993-1008. [PMID: 27836202 DOI: 10.1016/j.tips.2016.10.005] [Cited by in Crossref: 81] [Cited by in F6Publishing: 69] [Article Influence: 13.5] [Reference Citation Analysis]
25 Borga C, Businello G, Murgioni S, Bergamo F, Martini C, De Carlo E, Trevellin E, Vettor R, Fassan M. Treatment personalization in gastrointestinal neuroendocrine tumors. Curr Treat Options Oncol 2021;22:29. [PMID: 33641005 DOI: 10.1007/s11864-021-00825-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Patel A, Skitzki J. Melanoma trials that defined surgical management: Brief overview of current/upcoming adjuvant/neoadjuvant trials. J Surg Oncol 2022;125:38-45. [PMID: 34897704 DOI: 10.1002/jso.26746] [Reference Citation Analysis]
27 Wei J, Luo Y, Fu D. Early and late outcomes of bevacizumab plus chemotherapy versus chemotherapy alone as a neoadjuvant treatment in HER2-negative nonmetastatic breast cancer: a meta-analysis of randomized controlled trials. Onco Targets Ther 2018;11:9049-59. [PMID: 30588017 DOI: 10.2147/OTT.S186816] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
28 Valerio L, Giani C, Agate L, Molinaro E, Viola D, Bottici V, Matrone A, Puleo L, Lorusso L, Cappagli V, Ribechini A, Elisei R. Prevalence and Risk Factors of Developing Fistula or Organ Perforation in Patients Treated with Lenvatinib for Radioiodine-Refractory Thyroid Cancer. Eur Thyroid J 2021;10:399-407. [PMID: 34540710 DOI: 10.1159/000514182] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Shukla NA, Yan MN, Hanna N. The Story of Angiogenesis Inhibitors in Non-small-cell Lung Cancer: The Past, Present, and Future. Clin Lung Cancer 2020;21:308-13. [PMID: 32291211 DOI: 10.1016/j.cllc.2020.02.024] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
30 Wang L, Yu C, Wang J. Development of reporter gene assays to determine the bioactivity of biopharmaceuticals. Biotechnology Advances 2020;39:107466. [DOI: 10.1016/j.biotechadv.2019.107466] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
31 Calvetti L, Pilotto S, Carbognin L, Ferrara R, Caccese M, Tortora G, Bria E. The coming of ramucirumab in the landscape of anti-angiogenic drugs: potential clinical and translational perspectives. Expert Opinion on Biological Therapy 2015;15:1359-70. [DOI: 10.1517/14712598.2015.1071350] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
32 Huang J, Xiao J, Fang W, Lu P, Fan Q, Shu Y, Feng J, Zhang S, Ba Y, Zhao Y, Liu Y, Bai C, Bai Y, Tang Y, Song Y, He J. Anlotinib for previously treated advanced or metastatic esophageal squamous cell carcinoma: A double-blind randomized phase 2 trial. Cancer Med 2021;10:1681-9. [PMID: 33586360 DOI: 10.1002/cam4.3771] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
33 Wright M, Beaty JS, Ternent CA. Molecular Markers for Colorectal Cancer. Surg Clin North Am 2017;97:683-701. [PMID: 28501255 DOI: 10.1016/j.suc.2017.01.014] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
34 Ismail SI, Alshaer W. Therapeutic aptamers in discovery, preclinical and clinical stages. Adv Drug Deliv Rev 2018;134:51-64. [PMID: 30125605 DOI: 10.1016/j.addr.2018.08.006] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 4.5] [Reference Citation Analysis]
35 Park CS, Kim TK, Kim HG, Kim YJ, Jeoung MH, Lee WR, Go NK, Heo K, Lee S. Therapeutic targeting of tetraspanin8 in epithelial ovarian cancer invasion and metastasis. Oncogene 2016;35:4540-8. [PMID: 26804173 DOI: 10.1038/onc.2015.520] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 5.8] [Reference Citation Analysis]
36 Qi F, Hu X, Liu Y, Wang Z, Duan J, Wang J, Dong M. First-line pemetrexed-platinum doublet chemotherapy with or without bevacizumab in non-squamous non-small cell lung cancer: A real-world propensity score-matched study in China. Chin J Cancer Res. 2019;31:749-758. [PMID: 31814679 DOI: 10.21147/j.issn.1000-9604.2019.05.05] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
37 Ferro Desideri L, Traverso CE, Nicolò M. Abicipar pegol: an investigational anti-VEGF agent for the treatment of wet age-related macular degeneration. Expert Opin Investig Drugs 2020;29:651-8. [PMID: 32479126 DOI: 10.1080/13543784.2020.1772754] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
38 Bast RC, Zalutsky MR, Frankel AE. Monoclonal Serotherapy. In: Bast RC, Hait WN, Kufe DW, Weichselbaum RR, Holland JF, Croce CM, Piccart-gebart M, Wang H, Hong WK, Pollock RE, editors. Holland-Frei Cancer Medicine. Hoboken: John Wiley & Sons, Inc.; 2016. pp. 1-23. [DOI: 10.1002/9781119000822.hfcm065] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
39 Lee C, Chen H, Meir YJ, Ma DH, Wu W. Subconjunctival injection of bevacizumab for recurrent conjunctival papilloma: a case report. Canadian Journal of Ophthalmology 2017;52:e156-9. [DOI: 10.1016/j.jcjo.2017.03.011] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
40 Ferro Desideri L, Barra F, Ferrero S, Traverso CE, Nicolò M. Clinical efficacy and safety of ranibizumab in the treatment of wet age-related macular degeneration. Expert Opinion on Biological Therapy 2019;19:735-51. [DOI: 10.1080/14712598.2019.1627322] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
41 Tunsupon P, Harris K, Bower J, Alraiyes AH. Tracheobronchial Airway Necrosis: An Atypical Presentation of Recurrent Osteosarcoma. J Bronchology Interv Pulmonol 2017;24:59-62. [PMID: 27623422 DOI: 10.1097/LBR.0000000000000327] [Reference Citation Analysis]
42 Kim TK, Park CS, Jang J, Kim MR, Na HJ, Lee K, Kim HJ, Heo K, Yoo BC, Kim YM, Lee JW, Kim SJ, Kim ES, Kim DY, Cha K, Lee TG, Lee S. Inhibition of VEGF-dependent angiogenesis and tumor angiogenesis by an optimized antibody targeting CLEC14a. Mol Oncol 2018;12:356-72. [PMID: 29316206 DOI: 10.1002/1878-0261.12169] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
43 Iyer RV, Pokuri VK, Groman A, Ma WW, Malhotra U, Iancu DM, Grande C, Saab TB. A Multicenter Phase II Study of Gemcitabine, Capecitabine, and Bevacizumab for Locally Advanced or Metastatic Biliary Tract Cancer. American Journal of Clinical Oncology 2018;41:649-55. [DOI: 10.1097/coc.0000000000000347] [Cited by in Crossref: 25] [Cited by in F6Publishing: 13] [Article Influence: 6.3] [Reference Citation Analysis]
44 Higuchi T, Yokobori T, Takahashi R, Naito T, Kitahara H, Matsumoto T, Kakinuma C, Hagiwara S, Kuwano H, Shirabe K, Asao T. FF-10832 enables long survival via effective gemcitabine accumulation in a lethal murine peritoneal dissemination model. Cancer Sci 2019;110:2933-40. [PMID: 31278877 DOI: 10.1111/cas.14123] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
45 Farhat Ullah M, Ali Y, Ramzan Khan M, Ullah Khan I, Yan B, Ijaz Khan M, Malik MY. A review of COVID-19: Treatment Strategies and CRISPR/Cas9 gene editing technology approaches to the coronavirus disease. Saudi J Biol Sci 2021. [PMID: 34658640 DOI: 10.1016/j.sjbs.2021.10.020] [Reference Citation Analysis]
46 Xie C, Wan X, Quan H, Zheng M, Fu L, Li Y, Lou L. Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor. Cancer Sci. 2018;109:1207-1219. [PMID: 29446853 DOI: 10.1111/cas.13536] [Cited by in Crossref: 72] [Cited by in F6Publishing: 81] [Article Influence: 18.0] [Reference Citation Analysis]
47 Yi M, Jiao D, Qin S, Chu Q, Wu K, Li A. Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment. Mol Cancer. 2019;18:60. [PMID: 30925919 DOI: 10.1186/s12943-019-0974-6] [Cited by in Crossref: 104] [Cited by in F6Publishing: 115] [Article Influence: 34.7] [Reference Citation Analysis]
48 Touzani F, Geers C, Pozdzik A. Intravitreal Injection of Anti-VEGF Antibody Induces Glomerular Endothelial Cells Injury. Case Rep Nephrol 2019;2019:2919080. [PMID: 31934470 DOI: 10.1155/2019/2919080] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
49 Hao X, Zhu Y, Mu Y, Wang S, Li J, Xing P. Nab-paclitaxel in combination with Bevacizumab in patients with non-squamous non-small cell lung cancer after failure of at least one prior systemic regimen. J Cancer 2020;11:6421-8. [PMID: 33033525 DOI: 10.7150/jca.47072] [Reference Citation Analysis]
50 Gualdoni GS, Jacobo PV, Sobarzo CM, Pérez CV, Durand LAH, Theas MS, Lustig L, Guazzone VA. Relevance of angiogenesis in autoimmune testis inflammation. Mol Hum Reprod 2021;27:gaaa073. [PMID: 33313783 DOI: 10.1093/molehr/gaaa073] [Reference Citation Analysis]
51 Jamshaid H, Zahid F, Din IU, Zeb A, Choi HG, Khan GM, Din FU. Diagnostic and Treatment Strategies for COVID-19. AAPS PharmSciTech 2020;21:222. [PMID: 32748244 DOI: 10.1208/s12249-020-01756-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
52 Bear HD, Tang G, Rastogi P, Geyer CE, Zoon CK, Kidwell KM, Robidoux A, Baez-Diaz L, Brufsky AM, Mehta RS, Fehrenbacher L, Young JA, Senecal FM, Gaur R, Margolese RG, Adams PT, Gross HM, Costantino JP, Paik S, Swain SM, Mamounas EP, Wolmark N. The Effect on Surgical Complications of Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer: NRG Oncology/NSABP Protocol B-40. Ann Surg Oncol. 2017;24:1853-1860. [PMID: 27864694 DOI: 10.1245/s10434-016-5662-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
53 Borcherding N, Jethava Y, Vikas P. Repurposing Anti-Cancer Drugs for COVID-19 Treatment. Drug Des Devel Ther 2020;14:5045-58. [PMID: 33239864 DOI: 10.2147/DDDT.S282252] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
54 Matsumoto T, Mizumoto Y, Nakade K, Obata T, Matsuoka A, Myojo S, Ono M, Nakamura M, Fujiwara H. Subserous invasion of VEGF-C-producing cancer cells is a possible risk factor for ileal ulceration in the non-metastatic mucosal layer during bevacizumab-combined chemotherapy for recurrent ovarian cancer: A case report. Mol Clin Oncol 2017;7:820-4. [PMID: 29181171 DOI: 10.3892/mco.2017.1403] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
55 Díaz LP, Millán S, Chaban N, Campo AD, Spitzer E. Current state and comparison of the clinical development of bevacizumab, rituximab and trastuzumab biosimilars. Future Oncol 2021;17:2529-44. [PMID: 33904318 DOI: 10.2217/fon-2020-0923] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
56 Said R, Kakadiaris E, Piha-Paul S, Fu S, Falchook G, Janku F, Wheler JJ, Zinner R, Hong DS, Kurzrock R, Tsimberidou AM. Phase I clinical trial of lenalidomide in combination with bevacizumab in patients with advanced cancer. Cancer Chemother Pharmacol 2016;77:1097-102. [PMID: 27085994 DOI: 10.1007/s00280-016-3000-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
57 Le BT, Raguraman P, Kosbar TR, Fletcher S, Wilton SD, Veedu RN. Antisense Oligonucleotides Targeting Angiogenic Factors as Potential Cancer Therapeutics. Mol Ther Nucleic Acids 2019;14:142-57. [PMID: 30594893 DOI: 10.1016/j.omtn.2018.11.007] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 5.5] [Reference Citation Analysis]
58 Lee J, Kwon HJ, Kim M, Lee CS, Lee SC. Treatment response to intravitreal bevacizumab in small pigmented choroidal lesions with subretinal fluid. BMC Ophthalmol 2019;19:103. [PMID: 31053116 DOI: 10.1186/s12886-019-1108-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
59 La-Beck NM, Liu X, Shmeeda H, Shudde C, Gabizon AA. Repurposing amino-bisphosphonates by liposome formulation for a new role in cancer treatment. Semin Cancer Biol 2021;68:175-85. [PMID: 31874280 DOI: 10.1016/j.semcancer.2019.12.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
60 Verma H, Chandran A, Shaktivel P, Singh A, Kaushal S, Sikka K, Thakar A, Irugu DVK. The serum and tissue expression of vascular endothelial growth factor-in recurrent respiratory papillomatosis. Int J Pediatr Otorhinolaryngol 2021;146:110737. [PMID: 33979678 DOI: 10.1016/j.ijporl.2021.110737] [Reference Citation Analysis]
61 Li X, Abbas M, Li Y, Teng Y, Fang Y, Yu S, Wen Y, Wang L, Shi M. Comparative Effectiveness of Pemetrexed-platinum Doublet Chemotherapy With or Without Bevacizumab as First-line Therapy for Treatment-naive Patients With Advanced Nonsquamous Non-small-cell Lung Cancer in China. Clin Ther 2019;41:518-29. [PMID: 30846285 DOI: 10.1016/j.clinthera.2019.02.004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
62 Méndez O, Pérez J, Soberino J, Racca F, Cortés J, Villanueva J. Clinical Implications of Extracellular HMGA1 in Breast Cancer. Int J Mol Sci 2019;20:E5950. [PMID: 31779212 DOI: 10.3390/ijms20235950] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
63 Park J, Kim HO, Park KH, Wie MB, Choi SE, Yun JH. A 60% Edible Ethanolic Extract of Ulmus davidiana Inhibits Vascular Endothelial Growth Factor-Induced Angiogenesis. Molecules 2021;26:781. [PMID: 33546250 DOI: 10.3390/molecules26040781] [Reference Citation Analysis]
64 Angioni R, Liboni C, Herkenne S, Sánchez-Rodríguez R, Borile G, Marcuzzi E, Calì B, Muraca M, Viola A. CD73+ extracellular vesicles inhibit angiogenesis through adenosine A2B receptor signalling. J Extracell Vesicles 2020;9:1757900. [PMID: 32489531 DOI: 10.1080/20013078.2020.1757900] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
65 He Y, Kodali A, Wallace DI. Predictive Modeling of Neuroblastoma Growth Dynamics in Xenograft Model After Bevacizumab Anti-VEGF Therapy. Bull Math Biol 2018;80:2026-48. [DOI: 10.1007/s11538-018-0441-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
66 Aagre SV, Tonse M, Talele A, Sharma S, Advani SH. Bevacizumab based chemotherapy is a promising option in metastatic gallbladder adenocarcinoma. Mol Clin Oncol 2021;15:153. [PMID: 34178324 DOI: 10.3892/mco.2021.2315] [Reference Citation Analysis]
67 Buznyk O, Azharuddin M, Islam MM, Fagerholm P, Pasyechnikova N, Patra HK. Collagen-based scaffolds with infused anti-VEGF release system as potential cornea substitute for high-risk keratoplasty: A preliminary in vitro evaluation. Heliyon 2020;6:e05105. [PMID: 33033763 DOI: 10.1016/j.heliyon.2020.e05105] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
68 Aghajanian C, Goff B, Nycum LR, Wang YV, Husain A, Blank SV. Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer. Gynecol Oncol 2015;139:10-6. [PMID: 26271155 DOI: 10.1016/j.ygyno.2015.08.004] [Cited by in Crossref: 156] [Cited by in F6Publishing: 142] [Article Influence: 22.3] [Reference Citation Analysis]
69 Luis de Redín I, Expósito F, Agüeros M, Collantes M, Peñuelas I, Allemandi D, Llabot JM, Calvo A, Irache JM. In vivo efficacy of bevacizumab-loaded albumin nanoparticles in the treatment of colorectal cancer. Drug Deliv Transl Res 2020;10:635-45. [PMID: 32040774 DOI: 10.1007/s13346-020-00722-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
70 Gruslova A, Cavazos DA, Miller JR, Breitbart E, Cohen YC, Bangio L, Yakov N, Soundararajan A, Floyd JR, Brenner AJ. VB-111: a novel anti-vascular therapeutic for glioblastoma multiforme. J Neurooncol 2015;124:365-72. [PMID: 26108658 DOI: 10.1007/s11060-015-1853-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
71 He F, Bao Q, Bai J, Wang J, Zhai J, Yu Q, Guo W, Wu C, Zhang K, Shou W, Zhu G. Effects of I-125 seeds combined with anlotinib on tumor growth and bone metabolism in A549 tumor-bearing mice. Int J Radiat Biol 2021;97:1578-88. [PMID: 34491151 DOI: 10.1080/09553002.2021.1976860] [Reference Citation Analysis]
72 Morganti S, Curigliano G. Combinations using checkpoint blockade to overcome resistance. Ecancermedicalscience 2020;14:1148. [PMID: 33574893 DOI: 10.3332/ecancer.2020.1148] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
73 Uusi-Kerttula H, Legut M, Davies J, Jones R, Hudson E, Hanna L, Stanton RJ, Chester JD, Parker AL. Incorporation of Peptides Targeting EGFR and FGFR1 into the Adenoviral Fiber Knob Domain and Their Evaluation as Targeted Cancer Therapies. Hum Gene Ther 2015;26:320-9. [PMID: 25919378 DOI: 10.1089/hum.2015.015] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 3.7] [Reference Citation Analysis]
74 Kou F, Gong J, Li Y, Li J, Zhang X, Li J, Shen L. Phase I study of intraperitoneal bevacizumab for treating refractory malignant ascites. J Int Med Res 2021;49:300060520986664. [PMID: 33616416 DOI: 10.1177/0300060520986664] [Reference Citation Analysis]
75 Mollard S, Ciccolini J, Imbs DC, El Cheikh R, Barbolosi D, Benzekry S. Model driven optimization of antiangiogenics + cytotoxics combination: application to breast cancer mice treated with bevacizumab + paclitaxel doublet leads to reduced tumor growth and fewer metastasis. Oncotarget 2017;8:23087-98. [PMID: 28416742 DOI: 10.18632/oncotarget.15484] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
76 Cho R, Sakurai Y, Jones HS, Akita H, Hisaka A, Hatakeyama H. Silencing of VEGFR2 by RGD-Modified Lipid Nanoparticles Enhanced the Efficacy of Anti-PD-1 Antibody by Accelerating Vascular Normalization and Infiltration of T Cells in Tumors. Cancers (Basel) 2020;12:E3630. [PMID: 33291555 DOI: 10.3390/cancers12123630] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
77 Greig SL, Keating GM. Ramucirumab: A Review in Advanced Gastric Cancer. BioDrugs 2015;29:341-51. [PMID: 26341713 DOI: 10.1007/s40259-015-0138-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
78 Morera Y, Sánchez J, Bequet-romero M, Selman-housein K, de la Torre A, Hernández-bernal F, Martín Y, Garabito A, Piñero J, Bermúdez C, de la Torre J, Ayala M, Gavilondo JV. Specific humoral and cellular immune responses in cancer patients undergoing chronic immunization with a VEGF-based therapeutic vaccine. Vaccine 2017;35:3582-90. [DOI: 10.1016/j.vaccine.2017.05.020] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
79 Castellarin A, Zorzet S, Bergamo A, Sava G. Pharmacological Activities of Ruthenium Complexes Related to Their NO Scavenging Properties. Int J Mol Sci 2016;17:E1254. [PMID: 27490542 DOI: 10.3390/ijms17081254] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
80 Chakroun RW, Zhang P, Lin R, Schiapparelli P, Quinones-Hinojosa A, Cui H. Nanotherapeutic systems for local treatment of brain tumors. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2018;10. [PMID: 28544801 DOI: 10.1002/wnan.1479] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 5.2] [Reference Citation Analysis]
81 Wang J, Fan S, Feng Y, Zhang H, Zou W, Hu C. Antiangiogenic therapy for Wilms tumor in an adult and literature review. Anticancer Drugs 2019;30:640-5. [PMID: 30985306 DOI: 10.1097/CAD.0000000000000792] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
82 Kahn BM, Lucas A, Alur RG, Wengyn MD, Schwartz GW, Li J, Sun K, Maurer HC, Olive KP, Faryabi RB, Stanger BZ. The vascular landscape of human cancer. J Clin Invest 2021;131:136655. [PMID: 33258803 DOI: 10.1172/JCI136655] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
83 Ahn JW, Shalabi D, Correa-Selm LM, Dasgeb B, Nikbakht N, Cha J. Impaired wound healing secondary to bevacizumab. Int Wound J 2019;16:1009-12. [PMID: 31111622 DOI: 10.1111/iwj.13139] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
84 Morera-díaz Y, Gavilondo JV, Bequet-romero M, Sánchez Ramírez J, Hernández-bernal F, Selman-housein K, Perez L, Ayala-ávila M. Specific active immunotherapy with the HEBERSaVax VEGF-based cancer vaccine: From bench to bedside. Seminars in Oncology 2018;45:68-74. [DOI: 10.1053/j.seminoncol.2018.03.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
85 Das SK, Maji S, Wechman SL, Bhoopathi P, Pradhan AK, Talukdar S, Sarkar D, Landry J, Guo C, Wang XY, Cavenee WK, Emdad L, Fisher PB. MDA-9/Syntenin (SDCBP): Novel gene and therapeutic target for cancer metastasis. Pharmacol Res 2020;155:104695. [PMID: 32061839 DOI: 10.1016/j.phrs.2020.104695] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
86 Matsuoka A, Maeda O, Mizutani T, Nakano Y, Tsunoda N, Kikumori T, Goto H, Ando Y. Bevacizumab Exacerbates Paclitaxel-Induced Neuropathy: A Retrospective Cohort Study. PLoS One 2016;11:e0168707. [PMID: 27992556 DOI: 10.1371/journal.pone.0168707] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
87 Oudart JB, Villemin M, Brassart B, Sellier C, Terryn C, Dupont-Deshorgue A, Monboisse JC, Maquart FX, Ramont L, Brassart-Pasco S. F4, a collagen XIX-derived peptide, inhibits tumor angiogenesis through αvβ3 and α5β1 integrin interaction. Cell Adh Migr 2021;15:215-23. [PMID: 34308743 DOI: 10.1080/19336918.2021.1951425] [Reference Citation Analysis]
88 Ueda S, Saeki T, Takeuchi H, Shigekawa T, Yamane T, Kuji I, Osaki A. In vivo imaging of eribulin-induced reoxygenation in advanced breast cancer patients: a comparison to bevacizumab. Br J Cancer 2016;114:1212-8. [PMID: 27140309 DOI: 10.1038/bjc.2016.122] [Cited by in Crossref: 52] [Cited by in F6Publishing: 40] [Article Influence: 8.7] [Reference Citation Analysis]
89 Bertaut A, Truntzer C, Madkouri R, Kaderbhai CG, Derangère V, Vincent J, Chauffert B, Aubriot-Lorton MH, Farah W, Mourier KL, Boidot R, Ghiringhelli F. Blood baseline neutrophil count predicts bevacizumab efficacy in glioblastoma. Oncotarget 2016;7:70948-58. [PMID: 27487142 DOI: 10.18632/oncotarget.10898] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 5.3] [Reference Citation Analysis]
90 Peira E, Chindamo G, Chirio D, Sapino S, Oliaro-Bosso S, Rebba E, Ivanchenko P, Gallarate M. Assessment of In-Situ Gelling Microemulsion Systems upon Temperature and Dilution Condition for Corneal Delivery of Bevacizumab. Pharmaceutics 2021;13:258. [PMID: 33668475 DOI: 10.3390/pharmaceutics13020258] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
91 Dhillon S. Nintedanib: A Review of Its Use as Second-Line Treatment in Adults with Advanced Non-Small Cell Lung Cancer of Adenocarcinoma Histology. Targ Oncol 2015;10:303-10. [DOI: 10.1007/s11523-015-0367-8] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.9] [Reference Citation Analysis]
92 Song M, Finley SD. ERK and Akt exhibit distinct signaling responses following stimulation by pro-angiogenic factors. Cell Commun Signal 2020;18:114. [PMID: 32680529 DOI: 10.1186/s12964-020-00595-w] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
93 Wahl DR, Lawrence TS. Integrating chemoradiation and molecularly targeted therapy. Adv Drug Deliv Rev 2017;109:74-83. [PMID: 26596559 DOI: 10.1016/j.addr.2015.11.007] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
94 Kobayashi Y, Banno K, Kunitomi H, Nagai S, Takahashi T, Anko M, Iijima M, Takeda T, Matoba Y, Nakamura K, Tsuji K, Tominaga E, Aoki D. Is antidyslipidemic statin use for cancer prevention a promising drug repositioning approach? European Journal of Cancer Prevention 2019;28:562-7. [DOI: 10.1097/cej.0000000000000497] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
95 Wan W, Zhang X, Huang C, Chen L, Yang X, Bao K, Peng T. Monensin inhibits glioblastoma angiogenesis via targeting multiple growth factor receptor signaling. Biochem Biophys Res Commun 2020;530:479-84. [PMID: 32595038 DOI: 10.1016/j.bbrc.2020.05.057] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
96 Shirley M. Rucaparib: A Review in Ovarian Cancer. Target Oncol. 2019;14:237-246. [PMID: 30830551 DOI: 10.1007/s11523-019-00629-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]